TECHWIRE 30
(CIX: WRAL30)  1,196.76  up arrow+3.11  (0.26 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: Apple)  128.84  up arrow+0.38  (0.3 %)  Updated: 03:15 PM EST, Mar 02 2015
(NY: QUINTILES)  65.10  up arrow+0.12  (0.18 %)  Updated: 03:14 PM EST, Mar 02 2015
(OP: BASF SE)  95.59  down arrow-0.11  (-0.11 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: BioCryst)  10.29  up arrow+0.09  (0.88 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: BioDelivery)  15.45  up arrow+0.46  (3.03 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: CEMP)  32.12  down arrow-1  (-3.02 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: Cisco Systems)  30.16  up arrow+0.65  (2.19 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: Cree)  39.52  up arrow+0.26  (0.66 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: DARA)  0.97  down arrow-0.02  (-2.47 %)  Updated: 03:14 PM EST, Mar 02 2015
(NY: EMC CORPORATION)  28.89  down arrow-0.06  (-0.19 %)  Updated: 03:15 PM EST, Mar 02 2015
(NQ: Extreme Networks)  3.60  up arrow+0.05  (1.41 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: FB)  79.61  up arrow+0.64  (0.81 %)  Updated: 03:14 PM EST, Mar 02 2015
(NY: GLAXOSMITHKLINE)  47.79  up arrow+0.37  (0.78 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: GOOG)  569.90  up arrow+11.5  (2.06 %)  Updated: 03:15 PM EST, Mar 02 2015
(NY: IBM)  160.65  down arrow-1.29  (-0.8 %)  Updated: 03:15 PM EST, Mar 02 2015
(NY: LH)  123.19  up arrow+0.16  (0.13 %)  Updated: 03:14 PM EST, Mar 02 2015
(OP: Lenovo Group)  31.13  up arrow+0.55  (1.8 %)  Updated: 02:34 PM EST, Mar 02 2015
(NY: MRK)  58.63  up arrow+0.09  (0.16 %)  Updated: 03:15 PM EST, Mar 02 2015
(NQ: Microsoft Corp)  43.74  down arrow-0.11  (-0.25 %)  Updated: 03:15 PM EST, Mar 02 2015
(NQ: NTAP)  38.59  down arrow-0.06  (-0.16 %)  Updated: 03:15 PM EST, Mar 02 2015
(NY: NOVARTIS AG)  100.13  down arrow-2.27  (-2.22 %)  Updated: 03:14 PM EST, Mar 02 2015
(OP: Novozymes A/S)  48.88  down arrow-0.11  (-0.22 %)  Updated: 03:09 PM EST, Mar 02 2015
(NY: PFIZER)  34.64  up arrow+0.32  (0.93 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: Pozen)  7.33    (0 %)  Updated: 03:14 PM EST, Mar 02 2015
(NY: RED HAT)  69.49  up arrow+0.37  (0.54 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: BBRY)  11.08  up arrow+0.27  (2.45 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: Salix)  156.82  down arrow-0.39  (-0.24 %)  Updated: 03:14 PM EST, Mar 02 2015
(NQ: SQI)  17.28  down arrow-0.13  (-0.75 %)  Updated: 03:09 PM EST, Mar 02 2015

Posts tagged “Biotech & Life Science”

1:23 p.m. today

Long-time Duke researcher now No. 2 at FDA

FDA  Dr. Robert Califf, one of the nation's leading medical researchers, joined the Food and Drug Administration on Monday, taking on the agency's No. 2 leadership job at a critical juncture for prescription drugs, medical devices and tobacco products.

Updated 10:45 a.m. today

Premium Lock Report: NC biotech sector produces $73B, responsible for 61,000 jobs

Biotech  A newly released report from research firm Battelle documents the continuing growth of the biotech industry across North Carolina. Jobs are up, economic impact is surging, and average salaries are at $81,000. In fact, biotech employment grew more than 30 percent between 2000 and 2012 compared to an overall job growth rate of 1 percent.

10:37 a.m. today

Premium Lock Biotech industry impact case study: How Biogen spends $196M in state, employs 1,650 people

Inside the Battelle "Impact of Life Sciences in North Carolina" report: A break down on Biogen's "interactions," from jobs to partnerships and money spent with vendors.

Biogen's RTP plant Biogen's RTP plant

6:47 a.m. today

GSK, Novartis wrap up $21B asset swap, form joint venture

Drug giants GlaxoSmithKline and Novartis say they have formally closed on a deal valued at more than $21 billion to changes each company in dramatic fashion. Plus, they are moving ahead with a joint venture focusing on consumer healthcare.

A GSK-Novartis joint venture targets over-the-counter products A GSK-Novartis joint venture targets over-the-counter products

5:40 a.m. today

WTW in review: Last week's 70 headlines (Part Two)

Week in review Here's a look back at technology, life science and other related news as reported in WRAL TechWire last week. We published so many stories last week, we had to post this in two parts.

5:31 a.m. today

WTW in review: Last week's 70 headlines (Part One)

Week in review Here's a look back at technology, life science and other related news as reported in WRAL TechWire last week. We published so many stories last week, we had to post this in two parts.

Updated 5:29 a.m. today

Making news? Have an opinion? Share it with WRAL TechWire

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

Updated February 27

Ads for Android apps; Uber's hotel deal; Cempra's big 2015; Nickelodeon app; WhatsApp ban

Bulldog In today's Bulldog wrapup of business and technology news: Google places ads in Android apps store; Uber strikes a deal with hotel chain; Cempra looks for big 2015; Nickelodeon's new app; WhatsApp suspended in Brazil.

Updated February 25

Reddit, Google crack down on nude photos; GSK-Novartis deal nears close; Apple loses $539.M dispute; INC's first results; honor for Quintiles

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Reddit and Google are cracking down on nude photos; GSK says Novartis deal nears close; Apple loses a big patent verdict; INC reports results; an honor for Quintiles.

Updated February 25

GSK's nonprescription diet pill 'alli' back in stores after recall

"alli" back on sale GlaxoSmithKline's diet pill "alli" is now back in most U.S. stores. The drugmaker voluntary recalled the product last March after finding some packages in stores didn't contain real alli, indicating tampering after shipment.

February 24

Bronto's upbeat update; IBM targets hybrid cloud; Quintiles' new exec; YouTube for Kids half-baked?; Comcast earnings

In today's Bulldog wrapup of technology and life science news: Bronto's CEO offers a 2014 review via YouTube; IBM targets hybrid cloud; Quintiles adds a new exec; VentureBeat writer criticizes new YouTube for Kids; and Comcast income rises.

Updated February 24

Premium Lock Slideshow: Why Valeant is buying Salix in a $14B deal

In a presentation to investors, Valeant executives on Monday spelled out in great deal why the Canadian firm decided to buy Raleigh-based Salix in a deal worth $14 billion. We've got a slide show about the Valeant presentation.

Why Gastrointestinal Why Gastrointestinal

February 23

GSK-Novartis deal OK'd; Apple's $1.92B data centers; Argos buying HQ; Dish founder bis back; CommScope earnings

Bulldog In today's Bulldog wrapup of technology and life science news: The FTC approves the Novartis-GSK cancer drug deal; Apple plans new data centers in Europe; Argos is buying its new headquarters; Dish founder back as CEO; and CommScope reports a profit.

February 23

Salix stock dips, Valeant surges on deal news; law suits next?

Salix       Shares in Valeant Pharmaceuticals jumped 14 percent but Salix Pharmaceuticals fell slightly on Monday once stock markets opened and reacted to Sunday's announcement that Valeant is buying Salix in a deal valued at $14 billion. Three law firms are looking into the deal.

February 23

Premium Lock FDA news means $10M payday for BioDelivery Sciences

Raleigh-based BioDelivery Sciences will receive a $10 million milestone payment from partner Endo Pharmaceuticals now that the FDA has accepted a new drug application for the severe pain reliever system known as Belbuca.

How BDSI technology works How BDSI technology works

February 23

Premium Lock Tenax, formerly known as Oxygen Biotherapeutics, names CMO

Tenax The new chief medical officer is on board Tenax Therapeutics, which changed its name from Oxygen Biotherapeutics. And she received 25,000 options for company stock.

Updated February 23

Salix could pay $400M if deal with Valeant falls through

Merger Raleigh-based Salix Pharmaceuticals could have to pay as much as $400 million if its $14 billion deal to be acquired by Valeant falls through. Salix says it will not seek another offer but if another comes along and Salix accepts it, Valeant would be paid a termination fee of $356M plus related costs up to $50M.

Updated February 23

Raleigh-based Salix Pharmaceutical being acquired in $14B deal

A slide from a Salix presentation  Raleigh-based Salix Pharmaceuticals has agreed to be acquired by Canadian drugmaker Valeant Pharmaceuticals in a deal valued at some $14 billion. The boards of both companies have already agreed to the terms, which were announced Sunday.

Updated February 23

Premium Lock Sale won't end turmoil at Salix - look for more in short term

Salix       Sunday's announced acquisition of Salix by Valeant will not quite the turmoil that has engulfed one of the Triangle's best pharmaceutical success stories. In fact, in the short term, life is likely to get worse in a merger that is likely to lead to job cuts as part of $500 million in cost savings. Plus, the Triangle is losing another corporate headquarters.

February 23

Doctors say fitness trackers, health apps can boost care

Here's to your health Why give your doctors permission to incorporate data from fitness trackers and health apps into electronic patient records? Well, they might spot signs of an ailment sooner and suggest behavioral changes or medication before you land in the emergency room. They also might be able to monitor how you're healing from surgery or whether you're following a treatment regimen.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith